phenytoin has been researched along with Optic Nerve Diseases in 4 studies
Optic Nerve Diseases: Conditions which produce injury or dysfunction of the second cranial or optic nerve, which is generally considered a component of the central nervous system. Damage to optic nerve fibers may occur at or near their origin in the retina, at the optic disk, or in the nerve, optic chiasm, optic tract, or lateral geniculate nuclei. Clinical manifestations may include decreased visual acuity and contrast sensitivity, impaired color vision, and an afferent pupillary defect.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study tested the hypothesis that sodium channel blockade with phenytoin would result in neuroprotection of retinal ganglion cells (RGCs) and optic nerve axons in an experimental model of glaucoma." | 7.73 | Neuroprotection by sodium channel blockade with phenytoin in an experimental model of glaucoma. ( Hains, BC; Waxman, SG, 2005) |
| " This study tested the hypothesis that sodium channel blockade with phenytoin would result in neuroprotection of retinal ganglion cells (RGCs) and optic nerve axons in an experimental model of glaucoma." | 3.73 | Neuroprotection by sodium channel blockade with phenytoin in an experimental model of glaucoma. ( Hains, BC; Waxman, SG, 2005) |
| "A 19-year old man with cryptogenic simple partial and secondary generalized epilepsy developed blurred vision and xanthopsia after phenytoin loading for status epilepticus." | 3.72 | Acute visual dysfunction following phenytoin-induced toxicity. ( Deleu, D; Shenoy, R; Thakral, A, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Thakral, A | 1 |
| Shenoy, R | 1 |
| Deleu, D | 1 |
| Hains, BC | 1 |
| Waxman, SG | 2 |
| Hamard, H | 1 |
| Desbordes, JM | 1 |
| Fern, R | 1 |
| Ransom, BR | 1 |
| Stys, PK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Cohort Study of Association Between Steady State Phenytoin Treatment and Better Clinical Parameters of Glaucoma[NCT00739154] | 200 participants (Anticipated) | Observational | 2008-11-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for phenytoin and Optic Nerve Diseases
| Article | Year |
|---|---|
[Iatrogenic pathology of the optic nerve].
Topics: Adrenal Cortex Hormones; Antiprotozoal Agents; Chloramphenicol; Contraceptives, Oral; Ethambutol; Fe | 1982 |
3 other studies available for phenytoin and Optic Nerve Diseases
| Article | Year |
|---|---|
Acute visual dysfunction following phenytoin-induced toxicity.
Topics: Adult; Anticonvulsants; Color Perception; Epilepsy; Evoked Potentials, Visual; Humans; Male; Optic N | 2003 |
Neuroprotection by sodium channel blockade with phenytoin in an experimental model of glaucoma.
Topics: Administration, Oral; Animals; Axons; Cell Count; Cell Survival; Disease Models, Animal; Glaucoma; I | 2005 |
Pharmacological protection of CNS white matter during anoxia: actions of phenytoin, carbamazepine and diazepam.
Topics: Action Potentials; Animals; Axons; Carbamazepine; Diazepam; Dose-Response Relationship, Drug; Female | 1993 |